Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation.
暂无分享,去创建一个
K. Do | H. Kantarjian | A. Tsimberidou | E. Freireich | M. Keating | S. O'brien | F. Giles | S. Wen | R. Champlin | S. Lerner | I. Khouri | Susan C. Smith
[1] Michael L. Wang,et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] R. Gascoyne,et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] P. Gaulard,et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] A. Tsimberidou,et al. Richter syndrome , 2005, Cancer.
[5] P. Solal-Céligny,et al. Follicular lymphoma international prognostic index , 2006, Blood.
[6] Arthur Weiss,et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. , 2004, The New England journal of medicine.
[7] 謙 大間知. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.Coiffier B,et al.N Engl J Med 2002;346(4):235-42--CHOP+リツキシマブ併用療法は、CHOP療法を上回る治療法であり、DLBCLの治療動向に大きなimpactを与えた , 2004 .
[8] B. Andersson,et al. Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation and survival. , 2004, Experimental hematology.
[9] R. Fisher,et al. Diffuse aggressive lymphoma. , 2004, Hematology. American Society of Hematology. Education Program.
[10] Adrian Wiestner,et al. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. , 2003, Blood.
[11] P. Gaulard,et al. Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). , 2003, Blood.
[12] Emili Montserrat,et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. , 2003, The New England journal of medicine.
[13] H. Kantarjian,et al. Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte‐macrophage–colony stimulating factor (GM‐CSF) alternating with methotrexate and cytarabine plus rituximab and GM‐CSF in patients with Richter syndrome or fludarabine‐refractory chroni , 2003, Cancer.
[14] B. E. C. Oiffier,et al. CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma , 2002 .
[15] P. Mclaughlin,et al. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. , 2001, Blood.
[16] H. Kantarjian,et al. Fractionated Cyclophosphamide, Vincristine, Liposomal Daunorubicin (Daunoxome), and Dexamethasone (HyperCVXD) Regimen in Richter's Syndrome , 2001, Leukemia & lymphoma.
[17] M. Keating,et al. Allogeneic haematopoietic transplantation for Richter's syndrome , 2000, British journal of haematology.
[18] T J Hamblin,et al. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. , 1999, Blood.
[19] J. Armitage,et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] R. Foà,et al. Clinical characteristics and outcome of young chronic lymphocytic leukemia patients: a single institution study of 204 cases. , 1999, Blood.
[21] N. Ueno,et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] S. Jelić,et al. Richter syndrome with emphasis on large-cell non-Hodgkin lymphoma in previously unrecognized subclinical chronic lymphocytic leukemia. , 1997, Neoplasma.
[23] H. Kantarjian,et al. Richter's syndrome: a report on 39 patients. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] Emili Montserrat,et al. A predictive model for aggressive non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.
[25] P. Mclaughlin,et al. A proposal for a simple staging system for intermediate grade lymphoma and immunoblastic lymphoma based on the 'tumor score'. , 1992, Annals of oncology : official journal of the European Society for Medical Oncology.
[26] J. Armitage,et al. Diffuse histiocytic lymphoma complicating chronic lymphocytic leukemia , 1978, Cancer.
[27] D C Case,et al. Clinical staging of chronic lymphocytic leukemia. , 1977, The Journal of the Maine Medical Association.
[28] M. Richter. Generalized Reticular Cell Sarcoma of Lymph Nodes Associated with Lymphatic Leukemia. , 1928, The American journal of pathology.